Drugs / Pocenbrodib
Pocenbrodib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04575766 | Dec 2020 → Nov 2022 | prostate carcinoma | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06785636 | Feb 2025 → Jun 2028 expected | prostate carcinoma | Pathos AI, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pocenbrodib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06785636 ↗ |
| Known as | FT-7051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04575766 ↗ |
| Known as | FT-7051 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314476 ↗ |
| Known as | POCENBRODIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314476 ↗ |
| Action | Inhibit | “selective oral inhibitor of CBP/p300 bromodomain interaction” NCT06785636 ↗ |
| Modality | Small molecule | — CHEMBL5314476 ↗ |
| Route | Oral | “Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.” NCT04575766 ↗ |